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Summary
Objective: To assess if various biological responses to transforming growth factor- (TGF-) in chondrocytes are differentially regulated by
Smad-6 and Smad-7.
Design: Adenoviral overexpression of Smad-6 or -7 mRNA in a chondrocyte cell line was determined via semi-quantitative RT-PCR and
protein overexpression was studied by immunocytochemistry. Furthermore, the effect of Smad-6 and -7 overexpression on TGF--induced
PAI-1 and aggrecan mRNA upregulation was studied via quantitative RT-PCR. The effect of Smad-6 and -7 overexpression on
TGF--induced chondrocyte proliferation was studied via DNA quantification, whereas TGF--induced proteoglycan (PG) synthesis was
studied by 35S-sulfate incorporation.
Results: Adenoviral transfection of chondrocytes with Smad-6 and -7 resulted in strong upregulation of Smad-6 and -7 mRNA levels,
respectively. Immunocytochemistry showed overexpression of Smad-6 and -7 proteins in both the nucleus and cytoplasm. Smad-6
overexpression significantly inhibited TGF--stimulated chondrocyte proliferation, although proliferation was not completely abolished.
Smad-7 overexpression, however, completely antagonized the TGF- effect on proliferation. Smad-6 overexpression had no effect on
TGF--induced PAI-1 expression, while overexpression of Smad-7 completely blocked this TGF- effect. Additionally, overexpression of
Smad-7, but not Smad-6, totally prevented TGF--induced PG synthesis on the mRNA and protein levels.
Conclusions: Adenoviral transfection of chondrocytes with Smad-6 and -7 resulted in strong upregulation of Smad-6 and -7 mRNA and
protein levels. Furthermore, overexpression of Smad-7 in chondrocytes totally inhibited important TGF--mediated biological responses such
as proliferation and PG synthesis, while overexpressed Smad-6 had no or only a partial inhibitory effect on TGF- activity. We conclude that
in chondrocytes distinct TGF- activities are differentially regulated by Smad-6 and Smad-7.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is a joint disease affecting up to 70% of
the adult population and has as a main characteristic the
destruction of articular cartilage. OA is generally consid-
ered to be a chondrocyte disease. Although the exact
etiology of OA is unknown, a role for TGF- has been
implicated since high concentrations of active TGF- are
found in the synovial fluid of OA patients1,2 and TGF-
protein is expressed by osteoarthritic chondrocytes3. More-
over, loss of responsiveness to TGF- in transgenic mice
leads to OA4,5. We have previously shown that in aging
mice, chondrocytes become non-responsive to protective
TGF- functions, another indication that loss of TGF-
responsiveness may be involved in the initiation of OA6.
TGF- is a secreted signaling molecule that is involved in
a wide variety of cellular responses including proliferation,
differentiation, regulation of cell metabolism and extracellu-
lar matrix formation. Also for chondrocytes TGF- is an
important anabolic factor. In cultured chondrocytes the
synthesis of important extracellular matrix components
such as aggrecan and collagen type II is increased in
response to TGF-7–11, although it has also been reported
that TGF- can inhibit collagen type II synthesis12. Addition-
ally, TGF- inhibits matrix degradation via upregulation of
inhibitors of matrix degrading enzymes13,14. Furthermore,
TGF- is not only a strong stimulator of chondrocyte
proliferation15,16 but also an important regulator of
chondrocyte differentiation17–19. Also in vivo TGF- is cru-
cial to maintain normal chondrocyte differentiation state
and metabolism. This is reflected by the elevated incidence
of OA in several transgenic mouse strains with abrogated
TGF- signaling in chondrocytes5,6. Additionally, it has
been shown that during experimental OA articular chondro-
cytes show a dramatic decrease in the expression of
TGF-RII, which may lead to TGF- unresponsiveness
during OA20. Furthermore, we have previously shown that
TGF- is a very potent stimulator of chondrocyte proteogly-
can (PG) synthesis in vivo21,22 and that inhibition of endog-
enous TGF- during experimental OA leads to enhanced
cartilage PG loss23.
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Members of the TGF- superfamily to which TGF- and
bone morphogenetic proteins (BMPs) belong, induce the
formation of a heterotetrameric complex of the specific
serine/threonine kinase receptors. Signaling by the TGF-
family is initiated by the phosphorylation of type I receptors
by type II receptors. The signal is further transduced via
phosphorylation of intracellular mediators; so-called recep-
tor associated Smad proteins (R-Smads)24. TGF- signal-
ing is mediated by Smad-2 and -3, whereas BMPs signal
via Smad-1, -5 and -8. Phosphorylated R-Smads from both
TGF- and BMP pathways form a complex with Smad-4, a
common mediator or Co-Smad. The R-Smad/Co-Smad
complex propagates the signal to the nucleus, eventually
resulting in the activation or silencing of TGF- responsive
genes25.
The TGF- family signaling pathway initiated by
R-Smads and Co-Smads can be opposed by inhibitory
Smads (I-Smads): Smad-6 and -726–28. I-Smads act by
stably interacting with activated type I receptors, thus
preventing the phosphorylation of R-Smads26,29. Smad-6
preferential mode of action is competing with Smad-4 for
complex formation with phosphorylated Smad-129.
Smad-7 is thought to be an antagonist of both TGF- and
BMP activities, whereas Smad-6 is considered to be a BMP
inhibitor only. However, results are controversial and indi-
cate that TGF- activity is differentially regulated and seems
to depend on the TGF- response and cell type studied.
Studies have shown that Smad-7, but not Smad-6, not only
inhibits specific TGF- responses in epithelial lung and
renal tubule cells but also antagonizes TGF--induced lung
morphogenesis and lung fibrosis30–33. On the other hand,
although Smad-6 is often considered to be primarily a BMP
antagonist, inhibition of TGF- activity by Smad-6 has been
described. For instance, TGF--induced proliferation of
pancreatic cancer and epithelial cells could be inhibited by
Smad-634,35. Also TGF--mediated expression of plas-
minogen activator inhibitor-1 (PAI-1) and adipocyte differen-
tiation could be antagonized by Smad-635–37. Taken
together, negative regulation of TGF- activity by Smad-6
and -7 is not only cell type specific but also depends on the
TGF- response studied. Until now it is unknown how
Smad-6 and -7 regulate TGF--mediated responses in
chondrocytes.
In this study we investigated if Smad-6 and Smad-7 are
able to antagonize important TGF--mediated biological
responses in chondrocytes, such as chondrocyte prolifer-
ation and PG synthesis. We used adenoviral overexpres-
sion of Smad-6 and Smad-7 in a murine chondrocyte cell
line to specifically inhibit TGF- signaling. Overexpression
of Smad-7 totally inhibited TGF--mediated proliferation
and PG synthesis (protein and mRNA levels). Smad-6
significantly inhibited, but did not completely prevent, TGF-
-induced proliferation in chondrocytes. On the other hand,
Smad-6 had no effect on TGF--induced PG synthesis. So,
Smad-6 is at best a weak TGF- antagonist in chondro-
cytes, whereas we identified Smad-7 as a very efficient
inhibitor of TGF- activity in chondrocytes. We conclude
that in chondrocytes TGF- activity is differentially antago-
nized by Smad-6 and -7 depending on the TGF- response
studied.
Materials and methods
CELL CULTURE
Minc lung epithelial cells (MLEC) were cultured in mono-
layer at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM)/glutamax: 4500 mg/l glucose, pyridoxine
and sodium pyruvate (Life Technologies BV, Breda,
The Netherlands) supplemented with 10% fetal calf
serum (FCS) (ICN Biomedicals BV, Zoetermeer, The
Netherlands), penicillin (500 U/ml)/streptomycin sulfate
(500 µg/ml) (Life Technologies BV, Breda) and geneticin
sulfate (250 µg/ml) (Life Technologies BV, Breda, The
Netherlands). Cells were passaged for no more than
15 times.
H1 chondrocytes were cultured in monolayer in DMEM/
nut mix F12 (HAM) (Life Technologies BV, Breda, The
Netherlands) supplemented with 10% FCS and penicillin/
streptomycin sulfate at 37°C and 5% CO2. Generation of
this immortalized murine cell line is described elsewhere7.
Cells were passaged for a maximum of 20 times.
ADENOVIRAL VECTORS
Recombinant adenoviruses expressing full length
Smad-6 (Ad-Smad-6) and Smad-7 (Ad-Smad-7) were
generated as described elsewhere38. Adenoviruses were
amplified and purified as described previously39. As con-
trols, a recombinant adenovirus expressing luciferase
(Ad-Luc) or an adenovirus lacking an expression cassette
(Ad-DL70-3) was used. Cells were transfected with a
multiplicity of infection (MOI) of 1, 10 or 100. All adenovi-
ruses used had a comparable concentration of plaque
forming units (pfu; range=1.0–2.1×1010/ml); moreover, the
concentration of virus particles (virions) was also similar for
the different viruses used (range=0.9–1.5×1012/ml). All
transgenes were controlled by the CMV promoter.
MLEC ASSAY AND TRANSFECTION
The ability of Smad-6 and Smad-7 in inhibiting TGF-1
activity was tested using the MLEC assay. This assay is
based on the induction of PAI-1 promoter/luciferase con-
struct by TGF-, resulting in a dose dependent increase in
luciferase activity40. MLEC were transfected with
Ad-Smad-6, Ad-Smad-7 or Ad-DL70-3 with an MOI of 1, 10
or 100 in DMEM without FCS for 2 h at 37°C, 5% CO2.
Mock transfected cells were used as a control. After 2 h,
transfection medium was replaced with DMEM/glutamax
supplemented with 10% FCS, penicillin/streptomycin and
geneticin. Next, cells were incubated for 5 h before TGF-1(R&D Systems, Europe Ltd, Abingdon, UK) was added to
the transfected cells in a final concentration of 1.56 ng/ml
and cells were incubated for another 16 h at 37°C, 5% CO2.
Then, Bright-Glo luciferase assay reagent was added
(Promega, Leiden, The Netherlands). Luciferase activity
was measured using a Fluorstar Galaxy (BMG LabTech-
nologies GmbH, Offenburg, Germany) in the excitation
option using the following program: one cycle, 0.5 s inte-
gration time and positioning delay of 0.1 s. The effect of
transfection with Ad-Smad-6, Ad-Smad-7 or Ad-DL70-3 on
the TGF--induced luciferase activity was calculated from
TGF-1 standards added to mock transfected cells. Exper-
iments were performed at least two times and each stan-
dard or sample was tested in quadruplicate. Results were
analyzed via ANOVA.
TRANSFECTION OF CHONDROCYTES
H1 chondrocytes were transfected with Ad-Smad-6,
Ad-Smad-7, Ad-Luc or were mock transfected in DMEM/
HamsF12 without FCS for 2 h (MOI=10). After washing with
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physiological salt, DMEM/HamsF12 with 10% FCS was
added and cells were stimulated with or without TGF-1(end concentration 10 ng/ml) for the desired amount of
time.
MRNA ISOLATION AND RT REACTION
Cytoplasmic RNA was isolated using the RNeasy mini kit
according to the manufacturer’s protocol (Qiagen, Valencia,
CA, USA). Isolated RNA was treated with DNaseI (Life
Technologies BV, Breda, The Netherlands) to remove any
contaminating DNA. Next, 0.5 µg RNA was reverse
transcribed with 200 U Moloney-murine leukemia virus
reverse transcriptase (Life Technologies BV, Breda, The
Netherlands) in 50 mM Tris pH 8.3, 75 mM KCl, 3 mM
MgCl2, 10 mM dithiothreitol, 0.5 mM dNTPs, 20 U RNasin(Promega, Leiden, The Netherlands) and 0.5 µg
oligo(DT)15 (Eurogentec, Liege, Belgium). The mixture was
incubated at 39°C for 60 min, heated to 95°C for 10 min
and then cooled to 4°C.
SEMI-QUANTITATIVE AND QUANTITATIVE RT-PCR
Since TGF- is a strong stimulator of Smad-7 expression
in several cell types, we studied the effect of TGF-1 on
endogenous mRNA levels of Smad-6 and Smad-7 in
chondrocytes. Furthermore, overexpression of Smad-6 and
-7 mRNA after adenoviral transfection was determined via
semi-quantitative RT-PCR. The house keeping gene glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) was
used to correct for the amount of template used. RT-PCR
was performed with the following primers: GAPDH, 5′-
AACTCCCTCAAGATTGTCAGCA-3′ and 3′-ATGTCGTTG
TCCCACCACCT-5′, resulting in a 553 bp product; Smad-6,
5′-GTCAGCATTTTCTACGACCTA-3′ and 3′-AGTCGAA
CACCTTGATGGAGT-5′, resulting in a 262 bp product; and
Smad-7, 5′-TCCAGATACCCAATGGATTTTC-3′ and 3′-
AGCTGACTCTTGTTGTCCGAAT-5′, resulting in a 293 bp
product. RT-PCR was performed at a final concentration
of 50 mM KCl, 20 mM Tris pH 8.4, 1.5 mM MgCl2,
200 µM dNTPs, 0.4 µM of each primer and 40 U/ml
Taq-polymerase (Life Technologies BV, Breda, The
Netherlands). The mixture was overlaid with mineral oil and
amplified in a PTC-200 thermal cycler (MJ Research,
Peltier Thermal Cycler). The PCR protocol started with
1 min denaturation at 92°C, followed by annealing at 60°C
for 1 min and 1 min extension at 72°C. Semi-quantitative
PCR was performed as described elsewhere41. A factor of
1.8 per PCR cycle was taken to calculate the difference in
mRNA expression. It was determined that the PCR reaction
performed linearly at the point when the PCR product was
first detected. Experiments were performed at least two
times.
The effect of luciferase, Smad-6 and -7 overexpression
on TGF--induced PAI-1 and aggrecan mRNA overexpres-
sion was studied using quantitative RT-PCR with the fol-
lowing primer sets as designed using Primer Express
(Applied Biosystems Nieuwerkerk a/d IJsel, The
Netherlands): GAPDH, 5′-GGCAAATTCAACGGCACA-3′
and 5′-GTTAGTGGGGTCTCGCTCCTG-3′; aggrecan, 5′-
AGGCATGGTGCTTTGACAGTG-3′ and 5′-TCTACCCCA
ACCAAACCGG-3′; and PAI-1, 5′-ACGTCGTGGAAC
TGCCCTAC-3′ and 5′-CAGCGATGAACATGCTGAGG-3′.
Quantitative RT-PCR was performed with SYBR Green
PCR master mix according to the manufacturer’s
recommendations. Amplification and detection were
performed with an ABI Prism 7000 Sequence detection
system (Applied Biosystems, Nieuwerkerk a/d IJsel, The
Netherlands) under the following conditions: 94°C (15 s)
and 60°C (1 min) for 40 cycles. Threshold levels (CT
values) were determined using Sequence Detection
System software (Applied Biosystems). The amplification
efficiency was determined in a 10-fold standard dilution
range and for this 10-fold dilution was shown to be 3.25 for
PAI-1, 3.214 for GAPDH and 3.028 for aggrecan. Quanti-
tative RT-PCR was performed in duplo and for each exper-
imental group the CT of GAPDH was subtracted from the
CT of PAI-1 and aggrecan. The average delta CT of the
duplos was taken and upregulation or downregulation of
PAI-1 and aggrecan after stimulation with TGF-1 com-
pared to unstimulated cells was determined (expressed as
percentage). The experiment was repeated three times and
the values from mock transfected cells+TGF-1 was stated
as 100%. The values of the other experimental groups is
shown as a relative percentage.
IMMUNOCYTOCHEMISTRY OF SMAD-6 AND SMAD-7
H1 chondrocytes were cultured in four well Lab-Tek II
chamber slides (Nalge Nunc International, Naperville, IL,
USA) at a concentration of 2×105 cells/well for 16 h at
37°C, 5% CO2 to allow attachment. Then, chondrocytes
were transfected with MOI=10 with Ad-Smad-6, Ad-
Smad-7, Ad-Luc or were mock transfected for 2 h at 37°C,
5% CO2, after which the transfection medium was replaced
with normal culture medium. Cells were cultured for an
additional 48 h before cells were fixed in 2% paraformalde-
hyde, 4% sucrose for 5 min at room temperature (RT).
Subsequently, cells were permeabilized with 0.2% Triton-
X-100 in PBS during 30 min. After extensive washing with
PBS, endogenous peroxide was inactivated with 1% H2O2
in methanol for 30 min followed by washing with PBS.
Slides were incubated with rabbit anti-Smad-6 antibody
(Ab) (Zymed Laboratories, San Francisco, CA, USA), goat
anti-Smad-7 Ab (Santa Cruz Biotechnology, Heidelberg,
Germany) or as a control with rabbit or goat IgGs, respect-
ively, in a concentration of 1 µg/ml in 3% bovine serum
albumin (BSA)/PBS for 2 h at RT. After washing with PBS,
slides were incubated with the biotin-labeled secondary
horse anti-rabbit for the anti-Smad-6 Ab or rabbit anti-goat
for the anti-Smad-7 Ab in a concentration of 1 µg/ml in 3%
BSA/PBS for 1–2 h at RT. Subsequently, a biotin–
streptavidin detection system (Vectra elite kit, Vector Labo-
ratories Inc, Burlingham, CA, USA) was used according to
the manufacturer’s recommendations. Bound complexes
were visualized via reaction with 3′,3′diaminobenzidine
(DAB; Sigma Chemicals Co, St. Louis, MO, USA) and
H2O2. Cells were briefly counterstained with hematoxylin
and mounted with permount.
PG SYNTHESIS AND CHONDROCYTE PROLIFERATION
The effect of adenoviral overexpression of Ad-Smad-6,
Ad-Smad-7, Ad-Luc or mock transfected cells on TGF-1-
induced PG synthesis (35SO42− incorporation) and chondro-
cyte proliferation (DNA content) was studied. After 48 h
cells were pulse-labeled with 35SO42− (20 µCi/well) for 3 h at
37°C, 5% CO2. Next, a papain-carrier solution was added
to break down the extracellular matrix (60°C, 2 h): 1 mg
papain, 50 µg chondroitin sulfate, 0.2 M NaCl, 0.1 M NaAc,
10 mM cysteine-hydrochloride and 50 mM Na2EDTA per ml
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water. Incubation was followed by storage o/n at −20°C.
Subsequently, 600 µl sample solution was added to an
equal amount of cetylpyridium chloride (CPC) to precipitate
glycosaminoglycans and incubated for 2 h at 37°C followed
by centrifugation at 12 000 rpm for 10 min. The pellet was
washed three times with 0.05% CPC followed by centrifu-
gation after each wash step. The pellet was reconstituted
in 0.5 ml lumasolve (Lumac-LSC BV, Groningen, The
Netherlands) and incubated for 1 h at 60°C, after which the
pellet was resuspended thoroughly and 10 ml lipoluma
(Lumac-LSC BV) was added. Incorporated 35SO42− was
counted using a liquid scintillation counter. Each sample
was tested in triplicate.
Chondrocyte proliferation was studied via measurement
of DNA content. Double stranded DNA was selectively
stained with the fluorescent dye Picogreen according to the
manufacturer’s manual (Molecular Probes, OR, USA). The
DNA content was taken as an indirect measure for cell
number. After o/n storage at −20°C as described above, a
100 µl sample was taken to measure the DNA content of
each sample. To each sample an equal amount of
Picogreen reagent was added. A standard curve was used
to quantify DNA concentrations in the samples. Fluor-
escence was measured using the Fluorstar Galaxy with the
following program: excitation filter 485-P, emission filter
520-P, one cycle and 10 flashes. Gain was adjusted to the
highest concentration in the standard curve. Results were
analyzed via ANOVA.
From the paired results from 35SO42− incorporation and
DNA quantification the 35SO42− incorporation per cell was
calculated. Experiments were performed at least two times.
Triplicates were averaged and differences were analyzed
via ANOVA.
Results
MLEC ASSAY
To determine if adenoviral overexpression of Smad-6
and -7 resulted in blockage of TGF-1 activity, we made use
of the MLEC reporter assay for TGF-. As can be seen in
Fig. 1, transfection with Ad-DL70-3 at MOI 1 and 10
reduced luciferase activity by 11 and 19%, respectively. At
higher MOI, luciferase activity was even reduced by 25%.
These inhibitory effects on TGF-1 activity are probably due
to an aspecific virus effect. Transfection of Ad-Smad-6 at
MOI 1 and 100 significantly inhibited TGF-1 activity com-
pared to the effect of Ad-DL70-3 but TGF-1 activity was
not completely abolished by Smad-6 overexpression. In
contrast to Ad-DL70-3 and Ad-Smad-6, Ad-Smad-7 at an
MOI of 1 already blocked 84% of the luciferase activity
induced by 1.56 ng/ml TGF-1. At higher MOI the TGF-1-
induced luciferase activity was totally inhibited by Smad-7
overexpression. The observation that Ad-Smad-7 values
are even below background levels is probably due to the
inhibition of endogenous TGF- produced by MLEC or
TGF- present in FCS. The results indicate that already at
low MOI, Smad-7 totally inhibits the TGF-1-induced stimu-
lation of the PAI-1 promoter and the subsequent production
of luciferase. In contrast, only a partial inhibition of TGF-1
activity by Smad-6 overexpression was observed.
Fig. 1. Smad-6 and Smad-7 effects on TGF--induced PAI-1 promoter driven luciferase activity in MLEC. MLEC were transfected with
Ad-DL70-3, Ad-Smad-6 or Ad-Smad-7 at MOI 1, 10 and 100 in serum-free DMEM for 2 h. Next, medium was replaced with DMEM/10% FCS.
After another 5 h, 1.56 ng/ml TGF- was added. After 16 h incubation luciferase activity was measured via the Bright-Glo luciferase assay
reagent. The effect of adenoviral transfection was calculated from TGF- standards added to mock transfected cells. Standards and samples
were tested in quadruplicate and results were averaged and analyzed via ANOVA.
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SMAD-6 AND SMAD-7 EXPRESSION IN CHONDROCYTES
Semi-quantitative RT-PCR
I-Smads have been described to be part of an auto-
inhibitory feedback loop for TGF-. Therefore, the effects of
exogenously added TGF-1 on endogenous expression
levels of Smad-6 and -7 mRNAs were determined. Cultured
chondrocytes express Smad-6 and Smad-7 mRNA (results
not shown). TGF-1 stimulation (48 h) upregulated endog-
enous Smad-7 mRNA in chondrocytes in the order of
3.2-fold. We did not observe a detectable upregulation
of endogenous Smad-6 mRNA levels by TGF-1 in
chondrocytes after 48 h (results not shown).
Because adenoviral transfection of cells with an MOI of
100 resulted in a strong virus effect we used an MOI of 10
in all further experiments in order to minimize this effect.
Transfection of chondrocytes with Ad-Smad-6 resulted in
an upregulation of Smad-6 mRNA levels in the order of
eight PCR cycles compared to mock transfected, Ad-Luc
and Ad-Smad-7 transfected cells (results not shown). The
addition of TGF-1 had no additional effect on Smad-6
mRNA overexpression. Smad-7 mRNA levels were upregu-
lated nine cycles in Ad-Smad-7 transfected cells compared
to mock, Ad-Luc and Ad-Smad-6 transfected cells (results
not shown). The addition of TGF-1 did not affect the
adenovirally mediated Smad-7 mRNA overexpression.
Immunocytochemistry
We studied whether the strong mRNA overexpression of
Smad-6 and Smad-7 after adenoviral transfection resulted
in enhanced Smad-6 and Smad-7 protein expression.
Overexpression of Smad-6 and Smad-7 protein was inves-
tigated in transfected chondrocytes after 48 h using specific
anti-Smad Ab. Figure 2 shows high expression of Smad-6
in Ad-Smad-6 transfected cells, but not after transfection of
Ad-Smad-7, Ad-Luc or mock treated cells. Similarly, high
Smad-7 expression was detected in Ad-Smad-7 trans-
fected chondrocytes but not after Ad-Smad-6 transfection,
Ad-Luc transfection or mock transfection. Transfection effi-
ciency of chondrocytes with Ad-Smad-6 and -7 was in the
order of 70–80%, resulting in similar staining intensities of
Smad-6 and -7 [Fig. 2(A and B)]. Although I-Smads are
endogenous proteins only little staining was found in con-
trol transfected cells, indicating that endogenous protein
levels of Smad-6 and -7 are relatively low and that adeno-
viral transfection leads to Smad-6 and -7 protein expres-
sion in the cytoplasm and nucleus. For both I-Smads
staining seemed absent from certain cytoplasmic vesicles
of unknown origin. I-Smad staining of the nucleus was
predominantly perinuclear. Moreover, I-Smads seemed ab-
sent from certain regions of the nucleus, possibly repre-
senting the nucleoli. Substitution of the primary Ab with
control IgG did not result in any staining, indicating the
specificity of the Abs used (data not shown). Taken to-
gether, transfection of chondrocytes with Ad-Smad-6 and -7
leads to pronounced overexpression of Smad-6 and
Smad-7 protein, respectively.
SMAD-6 AND SMAD-7 BOTH INHIBIT TGF--INDUCED
CHONDROCYTE PROLIFERATION
Since TGF- is a potent inducer of chondrocyte prolifer-
ation, we studied if overexpressing I-Smads could prevent
this effect. Proliferation was monitored by measuring the
increase in DNA content, an indirect measure of cell
number. As Fig. 3 shows, treatment with TGF-1 in mock
transfected cells increased cell number by 41% compared
to untreated cells. Overexpression of luciferase already
caused a drop in cell number in comparison to mock
treatment. Despite this aspecific virus effect in the Ad-Luc
group, TGF-1 still significantly increased cell number as
compared to unstimulated Ad-Luc transfected chondro-
cytes (compare white bars with black ones). In contrast,
when comparing TGF-1-treated with non-treated chondro-
cytes our results indicate that Smad-6 overexpression
significantly inhibited but not completely abolished cell
proliferation. Smad-7 overexpression on the other hand
totally inhibited TGF-1-induced chondrocyte proliferation(Fig. 3).
SMAD-7 BLOCKS TGF- UPREGULATED AGGRECAN AND PAI-1
EXPRESSION
We studied the effect of Ad-Smad-6 and -7 transfection
on TGF--induced upregulation of aggrecan mRNA levels,
the most abundant PG in articular cartilage. The addition of
TGF-1 to mock transfected cells upregulated aggrecan
mRNA 2.9 PCR cycles compared to non-TGF- treated
cells. In Ad-Luc transfected cells a slight inhibition of
aggrecan mRNA expression was observed but this was not
significant. Also Ad-Smad-6 did not significantly inhibit
this TGF-1-induced upregulation (Table I). In contrast,
transfection of Ad-Smad-7 completely prevented the
upregulation of aggrecan mRNA induced by TGF-1.
We also studied PAI-1 mRNA expression in response to
TGF-. The addition of TGF-1 to mock transfected cells
resulted in upregulation of PAI-1 mRNA levels 1.9 PCR
cycles compared to non-treated cells. Table I shows that in
Ad-Luc and Smad-6 treated cells a mild inhibitory effect of
the transfection itself could be observed but this effect was
not significant. In contrast, Ad-Smad-7 overexpression
almost completely abolished the TGF-1-mediated
upregulation of PAI-1 expression.
SMAD-7 PREVENTS TGF--INDUCED PG SYNTHESIS
Because TGF- upregulated aggrecan on the mRNA
level, we set out to investigate if overexpression of Smad-6
or Smad-7 regulated TGF--induced PG synthesis. Figure
4 shows that after mock transfection, TGF-1 enhanced
chondrocyte PG synthesis by 31% after 48 h. Overexpres-
sion of luciferase via transfection with Ad-Luc had no effect
on the PG synthesis induced by TGF-1 compared to mock
treated cells (41%). Similarly, overexpression of Smad-6
showed no effect on TGF-1-induced PG synthesis com-
pared to luciferase transfection (40%). In contrast, overex-
pression of Smad-7 completely prevented TGF-1-induced
PG synthesis, indicating that Smad-7 but not Smad-6 is a
potent inhibitor of TGF-1-induced PG synthesis in
chondrocytes.
Discussion
OA is a joint disease with the destruction of articular
cartilage as a major characteristic. OA is regarded as a
chondrocyte disease. An important anabolic factor acting
on chondrocytes is TGF-. Recently, Smad-6 and -7 have
been described as novel intracellular regulators of TGF-
activity. However, the regulatory effect of these I-Smads on
TGF--induced responses in chondrocytes is unknown.
Here, we investigated if adenoviral overexpression of
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Fig. 2. Immunocytochemical localization of Smad-6 and Smad-7 after adenoviral overexpression. H1 chondrocytes were cultured in Lab-Tek
II chamber slides at a concentration of 2×105 cells/well. The next day, cells were transfected with MOI 10 with Ad-Luc, Ad-Smad-6 or
Ad-Smad-7 or were mock transfected. The next day, I-Smad overexpression was studied using anti-Smad-6 or anti-Smad-7 Ab followed by
incubation with the appropriate biotin-labeled secondary Ab. Ad-Smad-6 (A and C) and Ad-Smad-7 (B and D) transfected chondrocytes
incubated with anti-Smad-6 or anti-Smad-7 Ab, respectively. Note, the intense staining of cytoplasm and perinuclear staining of the nucleus.
Staining is absent from cytoplasmic vesicles and certain regions of the nucleus. (E) Ad-Smad-6 transfected chondrocytes incubated with
anti-Smad-7 Ab. Little Smad-7 staining is observed. (F) Ad-Smad-7 transfected chondrocytes incubated with anti-Smad-6 Ab. Few positive
cells are stained. Ad-Luc transfected chondrocytes incubated with anti-Smad-6 (G) or anti-Smad-7 Ab (H). Only faint staining is visible.
778 A. Scharstuhl et al.: Regulation of responses to TGF- by Smad-6 and -7
Smad-6 or Smad-7 results in inhibition of several TGF-1-
mediated responses in chondrocytes. Our results show that
Smad-6 only weakly inhibited TGF-1-induced cell prolifer-
ation, whereas Smad-7 totally blocked TGF-1-induced
chondrocyte proliferation and PG synthesis in chondro-
cytes.
Although Smad-6 and -7 are described as negative
regulators of TGF- activity, published results indicate that
TGF--induced biologic responses are not only differen-
tially regulated by I-Smads but are also cell type
specific30,32–36,42. The regulation of TGF- activity in
chondrocytes by I-Smads has never been studied. There-
fore, we set out to investigate if TGF-1-induced responses
such as chondrocyte proliferation and PG synthesis could
be regulated by Smad-6 and/or Smad-7.
First, we investigated the efficiency of Smad-6 and -7
overexpression in inhibiting TGF-1 responses in an MLEC
bioassay, based on the PAI-1 promoter driven production of
luciferase. Smad-7 showed to be very potent in inhibiting
TGF-1-induced activation of the PAI-1 promoter. Already
at low MOI TGF-1 activity could be almost completely
inhibited by Smad-7. Also Smad-6 overexpression had an
inhibitory effect on TGF-1 activity, however, the observed
inhibitory effect was only partial. These results show that
Smad-7 is a very potent antagonist of TGF-1, whereas
Smad-6 is a partial or weak inhibitor of TGF-1 activation in
MLEC.
We proceeded to use Smad-6 and Smad-7 overexpres-
sion to study regulation of TGF- signaling in chondrocytes.
First, we determined if adenoviral transfection resulted in
Fig. 3. Smad-6 and Smad-7 block TGF--induced chondrocyte proliferation. H1 chondrocytes were transfected at MOI 10 with Ad-Luc,
Ad-Smad-6 or Ad-Smad-7 or were mock transfected in DMEM/F12 without serum. After 2 h, medium was changed to DMEM/F12+10% FCS.
After another 5 h, 10 ng/ml TGF- was added and cells were incubated for 48 h. Chondrocyte proliferation was studied via measurement of
DNA content via staining with the fluorescent dye Picogreen. The DNA content was taken as an indirect measure for cell number.
Fluorescence was measured using the Fluorstar Galaxy. Gain was adjusted to the highest concentration in the standard curve. Results were
analyzed via ANOVA. *Significantly more proliferation than in non-stimulated (−TGF-) group.
Table I
Smad-7 inhibits TGF--induced upregulation of PAI-1 and aggrecan mRNA
Treatment* Aggrecan PAI-1
Average† SD Average† SD
Ad-Luc 35.7 0.65 32.3 2.36
Ad-Smad-6 38.0 1.74 33.4 1.70
Ad-Smad-7 99.9 6.33 88.4 2.63
*H1 chondrocytes were transfected with adenoviruses (MOI=10) expressing luciferase, Smad-6, Smad-7 or were mock transfected. The
next day, cells were stimulated with TGF- (10 ng/ml) or not stimulated for 4 h.
†Via quantitative PCR GAPDH, the PAI-1 and aggrecan mRNA levels were determined. GAPDH levels were used to correct for the amount
of template used. The upregulation for PAI-1 or aggrecan mRNA after TGF- stimulation vs non-stimulated cells was determined. The
upregulation of PAI-1 and aggrecan mRNA by TGF- in mock transfected cells was stated as 100%. The relative inhibition of TGF- activity
in percentages is shown.
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overexpression of I-Smad mRNA and protein levels. Our
results show that mRNA levels are indeed strongly upregu-
lated after transfection. Moreover, this mRNA overexpres-
sion resulted in pronounced overexpression of both I-Smad
proteins throughout the chondrocyte. It has been reported
that I-Smads are predominantly localized in the nucleus in
the absence of TGF-, whereas upon receptor activation
I-Smads translocate to the cytoplasm30. On the other hand,
also perinuclear and cytoplasmic staining for I-Smads have
been described42. Our results indicate that Smad-6 as well
as Smad-7 were localized throughout the cytoplasm and
were only absent from certain cytoplasmic vesicles.
Nuclear staining for Smad-6 and Smad-7 was also
observed, although certain nuclear regions, probably
representing nucleoli, were not or only weakly stained.
Although we detected endogenous I-Smad mRNA levels,
only very light staining for endogenous I-Smads could be
visualized. Since the used Abs cross-react with murine
Smad-6 and Smad-7 the endogenous protein levels for
Smad-6 and -7 are probably low in H1 chondrocytes but
protein levels are very high after adenoviral transfection.
It has been well described that chondrocytes respond to
TGF- stimulation by increasing proliferation and PG syn-
thesis. It is unknown, however, if these biological TGF-
effects can be regulated by Smad-6 or -7. To better under-
stand TGF- regulation in chondrocytes we made use of
adenoviral overexpression of Smad-6 and -7 and studied if
Smad-6 and -7 are capable of inhibiting different TGF-1-
mediated responses. As our results show, Smad-7 not only
completely blocked TGF-1-induced chondrocyte prolifer-
ation but also totally inhibited TGF-1-induced PG syn-
thesis (35S-sulfate incorporation+aggrecan mRNA levels).
Moreover, TGF-1-induced PAI-1 expression could be
totally blocked by Smad-7 overexpression.
Regulatory activity of Smad-6 showed to be dependent
on the TGF- response studied. Whereas TGF-1-induced
chondrocyte proliferation could be partially inhibited by
Smad-6, we observed no inhibition at all in TGF-1-
mediated PG synthesis on mRNA or protein level. Also the
upregulation of PAI-1 mRNA by TGF-1 could not be
antagonized by Smad-6. Since both the mRNA and protein
levels of Smad-6 and -7 after adenoviral overexpression
are comparable, the observed differences in TGF-1 block-
age between Smad-6 and -7 are most likely not due to a
difference in amount of the different I-Smads. In fact,
the small differences found on mRNA and protein levels
could easily be explained by differences in primer and Ab
affinities.
Our results demonstrate that Smad-6 is a poor inhibitor
of TGF-1 activity in chondrocytes. Since TGF- can induce
the expression of BMPs, it is tempting to speculate that the
effects observed for Smad-6 are due to inhibition of endog-
enous BMP rather than inhibition of exogenous TGF-
activity. This would imply that endogenous BMPs do not
contribute to stimulation of PG synthesis in H1 chondro-
cytes. Alternatively, since Smad-6 had a significant effect
on proliferation, endogenous BMPs may play a role in
chondrocyte cell growth. On the other hand, Ota et al. have
recently shown that TGF- can signal via different type I
receptors depending on the cell type studied43. In endo-
thelial cells TGF- could bind to ALK-1, a type I receptor
that normally transduces signals via the BMP-activated
Fig. 4. Smad-7 inhibits TGF--induced PG synthesis in chondrocytes. H1 chondrocytes were transfected at MOI 10 with Ad-Luc, Ad-Smad-6
or Ad-Smad-7 or were mock transfected in DMEM/F12 without serum. After 2 h, medium was changed to DMEM/F12+10% FCS. After
another 5 h, 10 ng/ml TGF- was added and cells were incubated for 48 h, pulse-labeled with 35SO42− (20 µCi/well), followed by incubation
with papain-carrier solution. Subsequently, glycosaminoglycans were precipitated and incorporated 35SO42− was counted using a liquid
scintillation counter. From the paired results from 35SO42− incorporation and proliferation the 35SO42− incorporation per cell was calculated.
Triplicates were averaged and differences were analyzed via ANOVA.
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Smad-1/Smad-5. This ALK-1-mediated transcriptional
regulation induced by TGF- resulted in completely differ-
ent cell activation compared to signal transduction medi-
ated by the common TGF- receptor ALK-5. Possibly, in
chondrocytes TGF- signaling is also mediated by different
type I receptors leading to activation of different sets of
R-Smads that in turn are differentially regulated by
I-Smads. So, regulation of proliferation might be mediated
by both ALK-1 and -5, whereas PG synthesis is controlled
by ALK-5 only.
In conclusion, our results show that Smad-7 is a potent
antagonist of various TGF- responses in chondrocytes.
Smad-6 was able to antagonize TGF- activity in some but
not in all responses studied. Our results suggest that
distinct TGF- responses in chondrocytes are differentially
regulated by I-Smads.
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